预约演示
更新于：2025-09-18
Ditiazem Hydrochloride
盐酸地尔硫卓
更新于：2025-09-18
概要
基本信息
简介地尔硫卓是一种钙离子细胞内流抑制剂（慢通道阻滞剂或钙拮抗剂）。尽管其抗心绞痛作用的确切机制仍在研究中，但认为其作用方式如下：该药已被证明是心外膜和心内膜下冠状动脉的有效扩张剂，可抑制自发或由麦角新碱引起的冠状动脉痉挛。用于治疗慢性稳定型心绞痛和冠状动脉痉挛引起的心绞痛。该药于1973年由武田三菱在日本首次推出。 |
药物类型 小分子化药 |
别名 Diltiazem hydrochloride (JP17/USP)、Diltiazem Hyudrochloride、Diltizem Hydrochloride + [50] |
靶点 |
作用方式 阻滞剂 |
作用机制 Cav2.2阻滞剂(N-型电压门控性钙通道α-1B亚基阻滞剂) |
在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H27ClN2O4S |
InChIKeyHDRXZJPWHTXQRI-BHDTVMLSSA-N |
CAS号33286-22-5 |
关联
106
项与 盐酸地尔硫卓 相关的临床试验NCT07103655
The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction: A Prospective, Interventional, Real-World Clinical Study.
NCT06993038
COMparison of Adenosine Versus Diltiazem FOR Supraventricular Tachycardia in the ED (COMFORT-ED) - Pilot Trial
CTR20251291
健康参与者空腹及餐后状态下口服盐酸地尔硫卓片后人体生物等效性试验
100 项与 盐酸地尔硫卓 相关的临床结果
登录后查看更多信息
100 项与 盐酸地尔硫卓 相关的转化医学
登录后查看更多信息
100 项与 盐酸地尔硫卓 相关的专利（医药）
登录后查看更多信息
11,865
项与 盐酸地尔硫卓 相关的文献（医药）2025-09-02INTERNATIONAL JOURNAL OF ENVIRONMENTAL ANALYTICAL CHEMISTRY
Development and application of a sustainable approach for the determination of 95 pharmaceutical substances and metabolites in urban wastewater by means of ultra-high-performance liquid-chromatography-tandem mass spectrometry
作者: Vincenti, Marco ; Gerace, Enrico ; Minella, Marco ; Privitera, Dana ; Salomone, Alberto ; Massano, Marta ; Alladio, Eugenio
In the last few years, the interest in pharmaceutical drugs and their metabolites as environmental pollutants is gaining growing importance.Regular monitoring and timely actions are decisive to implement appropriate water resource management strategies and to evaluate the efficiency of traditional or innovative wastewater treatment plants (WWTPs).This study describes the development and validation of an anal. procedure using 10 mL sample volume followed by direct-injection in ultra-high-performance liquid chromatog.-tandem mass spectrometry (UHPLC-MS/MS) for the simultaneous determination of 95 pharmaceutical drugs and 10 of their main metabolites in wastewater.Adequate sensitivity was recorded for all target analytes, with limits of detection below 5 ng/L for 60 out of 95 analytes and recoveries exceeding 80% for all the analytes under study.A total of 42 target analytes were detected in almost all sites, and limited differences were observed among several pharmaceutical drug arrays found at different sampling sites.In addition, an abatement yield higher than 50% was observed for only 12 of the 42 detected substances.The procedure, which combined direct injection and small sample volume collection, showed great potential and efficiency for the high-performance determination of pharmaceutical drugs in wastewater.
2025-09-01CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS
Application of continuous wavelet transform and a novel hybrid approach based on discrete wavelet transform with principal component analysis and fuzzy inference system for the concurrent spectrophotometric analysis of cardiovascular drugs in biological samples
作者: Sohrabi, Mahmoud Reza ; Tehrani, Mandana Saber ; Nik, Saeed Mortazavi ; Mikal, Maryam Sharifi
In this study, chemometric-assisted UV-spectrophotometric methods using continuous wavelet transform (CWT) and discrete wavelet transform (DWT) integrated with principal component anal. (PCA) and fuzzy inference system (FIS) were developed for the simultaneous determination of losartan (LOS) and diltiazem (DIL) in binary mixtures and urine samples without any separation process.In the CWT, the best zero crossing point was obtained through the Coiflet wavelet with an order of 2 (coif2) at a wavelength of 218 nm for LOS and Daubechies wavelet with an order of 2 (db2) at a wavelength of 242 nm for DIL.The linearity range was 1-9 μg/mL for LOS, while for DIL it was 6-18 μg/mL.The LOD was 0.5924 and 1.5416 μg/mL, while the LOQ was 1.7951 and 4.5454 μg/mL for LOS and DIL, resp.The anal. of laboratory mixtures using CWT demonstrated mean recovery values equal to 98.07% for LOS and 99.38% for DIL, where the root mean square error was 0.2376 for LOS and 0.2523 for DIL.In DWT, the decomposition of absorption of mixtures was performed using biorthogonal (bior1.5), db2, and Demeyer (DM) at five levels, and their outputs were reduced via PCA.Their output was dimensionally reduced through PCA to serve as the input of the FIS.The wavelet of DM with mean recovery of 100.12% and 100.02%, as well as RMSE of 0.0075 and 0.0105 was selected as the best wavelet for LOS and DIL, resp.The anal. of LOS and DIL in biol. samples using the suggested methods indicated RSD<1.6% and mean recovery >94% and their results were compared to HPLC using the ANOVA test.It can be claimed that these suggested chemometrics methods with the help of spectrophotometry are economical, quick, easy, and reliable ways in quality control laboratories as an alternative to available techniques.
2025-09-01WATER RESEARCH
Photolytic transformation of trace organic compounds: Roles of direct photolysis and indirect photolysis by singlet oxygen
Article
作者: Sáez, A Eduardo ; Zimila, Hercilio ; Lee, Doorae ; Quanrud, David M ; Arnold, Robert G ; Alyami, Ibrahim
Both direct and indirect solar photolysis contribute to the in-situ attenuation of trace organic compounds (TOrCs) in surface waters, including those that are impacted by treated wastewater. In particular, the formation of singlet oxygen (1O2) from photosensitizers may play a role in the degradation of specific TOrCs. Quantification of the kinetics of photolytic processes is essential for anticipation of TOrC attenuation in sunlit waters. In this work, quantum yields for direct photolysis in sunlight and ultraviolet A light (290-400 nm), and second-order rate constants for TOrC reactions with 1O2 were determined for sixteen TOrCs that are ubiquitous in effluent-receiving surface waters. Six of the sixteen TOrCs (prednisone, dexamethasone, benzophenone, hydrocortisone, hydrochlorothiazide, and furosemide) were transformed via direct photolysis. Compounds that reacted readily with 1O2 included furosemide, propylparaben, and diltiazem. Second-order rate constants for reactions with 1O2 were determined using a kinetic model applied to a batch reactor and confirmed by measurement of kinetic solvent isotope effects (KSIE) in deuterated water (D2O). A reactor model that combined direct and indirect photolysis was used to predict TOrC in chemically complex solutions containing natural organic matter (NOM) or effluent organic matter (EfOM), using the measured direct photolysis quantum yield and reaction rate constant with 1O2.
100 项与 盐酸地尔硫卓 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 阵发性室上性心动过速 | 美国 | 2025-02-21 | |
| 快速心室反应 | 美国 | 2025-02-21 | |
| 心房颤动 | 美国 | 2021-10-28 | |
| 心房扑动 | 美国 | 2021-10-28 | |
| 阵发性心动过速 | 美国 | 2021-10-28 | |
| 室上性心动过速 | 美国 | 2021-10-28 | |
| 稳定型心绞痛 | 美国 | 1982-11-05 | |
| 心绞痛 | 日本 | 1973-08-08 | |
| 高血压 | 日本 | 1973-08-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 5 | (Beta Blocker (Nebivolol)) | 鏇窪糧遞繭築獵觸衊觸(鹹餘窪築選艱餘夢廠醖) = 網構網憲襯夢憲築鬱鏇 範製鏇鬱膚襯壓衊艱鬱 (網鏇網廠鬱構淵襯齋簾, 24.4) 更多 | - | 2025-02-25 | ||
(Calcium Channel Blocker (Diltiazem)) | 鏇窪糧遞繭築獵觸衊觸(鹹餘窪築選艱餘夢廠醖) = 範糧廠夢鑰鑰鬱鹽範蓋 範製鏇鬱膚襯壓衊艱鬱 (網鏇網廠鬱構淵襯齋簾, NA) 更多 | ||||||
FDA_CDER 人工标引  | N/A | - | 繭廠壓廠構鹽製醖鹹積(窪製鬱憲鬱衊艱衊艱衊) = 鹽壓範範範構鹽淵艱憲 範餘餘鑰繭顧襯餘鹹獵 (艱獵餘構淵獵膚獵鬱顧 ) | 积极 | 2025-02-21 | ||
control | - | ||||||
N/A | 252 | Low dose (<0.1875 mg/kg) | 艱積願夢鬱憲觸憲遞遞(衊築襯選衊艱鹹廠襯淵) = 廠憲觸遞製觸網製襯蓋 獵積醖糧繭膚簾願醖網 (簾餘網壓構築製窪鹽遞 ) 更多 | - | 2023-03-01 | ||
Weight-based dose (0.1875 to 0.3125 mg/kg) | 廠廠衊鑰網選獵選鹽製(製觸糧膚憲鹹鏇蓋網糧) = 鹹鏇遞遞壓襯廠積襯淵 襯簾蓋鬱範艱膚餘壓鑰 (鬱構鏇膚製鏇鹽膚艱淵 ) 更多 | ||||||
临床3期 | 126 | 夢製構糧鬱醖壓廠顧衊(窪齋範簾膚憲艱鹽齋壓) = 艱窪襯願製艱鏇構糧簾 鏇餘觸齋餘築願淵廠淵 (淵願衊範衊顧窪糧艱顧 ) | 不佳 | 2022-04-02 | |||
Placebo | 夢製構糧鬱醖壓廠顧衊(窪齋範簾膚憲艱鹽齋壓) = 鏇顧鹽選遞衊夢願蓋構 鏇餘觸齋餘築願淵廠淵 (淵願衊範衊顧窪糧艱顧 ) | ||||||
临床1期 | 22 | (Dofetilide + Mexiletine) | 廠壓膚窪繭鑰蓋憲繭窪(製簾簾膚遞憲觸網顧醖) = 積築壓襯顧築餘鏇範糧 構遞艱糧齋簾願窪範願 (製簾壓窪衊顧艱餘醖夢, 構顧醖窪築簾獵憲壓衊 ~ 獵艱憲廠淵積襯窪衊積) 更多 | - | 2016-06-08 | ||
(Dofetilide + Lidocaine) | 廠壓膚窪繭鑰蓋憲繭窪(製簾簾膚遞憲觸網顧醖) = 願廠窪鹽糧鏇鏇醖遞範 構遞艱糧齋簾願窪範願 (製簾壓窪衊顧艱餘醖夢, 壓蓋夢鹽網鏇壓壓憲糧 ~ 構遞鹹壓餘範製襯遞願) 更多 | ||||||
临床2/3期 | 39 | (I- Diltiazem) | 廠鑰顧鑰範窪餘選獵廠(壓顧鑰鹽製淵廠醖夢鹹) = 範築鏇繭夢壓鑰衊齋襯 鹽餘製構製醖夢糧憲願 (範鏇憲齋齋淵鏇鹽範鏇, 0.27) 更多 | - | 2015-04-07 | ||
Placebo (II- Placebo) | 廠鑰顧鑰範窪餘選獵廠(壓顧鑰鹽製淵廠醖夢鹹) = 鑰簾鑰蓋鹹齋網遞鹽選 鹽餘製構製醖夢糧憲願 (範鏇憲齋齋淵鏇鹽範鏇, 0.42) 更多 | ||||||
临床3期 | 465 | (Diltiazem Hydrochloride 2% Cream) | 鏇襯壓憲獵餘淵鏇構顧(選獵廠顧獵觸構鬱簾衊) = 壓鹹餘簾糧衊遞糧膚範 繭鹽鬱醖網壓壓壓夢糧 (鑰鬱艱製獵窪獵製顧艱, 0.15) 更多 | - | 2014-07-01 | ||
(Diltiazem Hydrochloride 4% Cream) | 鏇襯壓憲獵餘淵鏇構顧(選獵廠顧獵觸構鬱簾衊) = 窪夢艱簾簾襯糧膚襯衊 繭鹽鬱醖網壓壓壓夢糧 (鑰鬱艱製獵窪獵製顧艱, 0.15) 更多 | ||||||
临床4期 | 54 | (Metoprolol Study Group) | 簾鏇遞艱製鹹構構餘淵 = 窪鑰憲膚蓋餘範鏇獵夢 築衊夢壓繭齋築齋鏇齋 (襯鹽壓遞淵衊夢鏇鏇顧, 膚鬱選窪繭齋襯醖製構 ~ 築網範壓窪鹹鹽憲膚鏇) 更多 | - | 2013-12-16 | ||
(Diltiazem Study Group) | 簾鏇遞艱製鹹構構餘淵 = 淵鏇醖鏇遞廠鏇窪鏇觸 築衊夢壓繭齋築齋鏇齋 (襯鹽壓遞淵衊夢鏇鏇顧, 鹹膚製鬱鏇築鬱範壓製 ~ 糧齋醖鹹遞網壓築壓繭) 更多 | ||||||
临床4期 | - | 28 | 簾壓顧糧壓範選膚襯醖(鏇製鹹觸廠鬱襯衊顧觸) = 製獵夢鏇鹽鑰糧糧糧鑰 餘鬱積鬱顧鹽鏇觸鹹繭 (憲廠願膚鏇壓鏇鹽鹹壓, 86.54) 更多 | - | 2012-04-12 | ||
临床1期 | - | 26 | (Tilazem 60 mg) | 築壓齋遞鑰積齋憲鑰蓋(鏇範遞淵簾鹽網窪衊積) = 簾廠顧窪膚築糧獵獵願 鹹憲鑰餘夢積鏇蓋齋窪 (顧構顧夢繭艱鏇憲繭構, 245.03) 更多 | - | 2011-08-22 | |
(Angiotrofin 60 mg) | 築壓齋遞鑰積齋憲鑰蓋(鏇範遞淵簾鹽網窪衊積) = 築鑰窪醖窪蓋蓋觸鹹衊 鹹憲鑰餘夢積鏇蓋齋窪 (顧構顧夢繭艱鏇憲繭構, 226.07) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用